Literature DB >> 21247218

Pharmacovigilance and the null hypothesis: do we do much for public health?

I Ralph Edwards, Ambrose Isah.   

Abstract

Mesh：

Year:  2011        PMID： 21247218     DOI： 10.2165/11588420-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  12 in total

1.  The lay user perspective on the quality of pharmaceuticals, drug therapy and pharmacy services--results of focus group discussions.

Authors:  Janine Morgall Traulsen; Anna Birna Almarsdóttir; Ingunn Björnsdóttir
Journal:  Pharm World Sci       Date:  2002-10

2.  Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.

Authors:  Priya Bahri
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

Review 3.  Preventability of drug-related harms - part I: a systematic review.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

4.  A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.

Authors:  John Abraham; Courtney Davis
Journal:  Soc Sci Med       Date:  2005-03-02       Impact factor: 4.634

5.  What are the real lessons from Vioxx?

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  First do no harm. Improving drug safety through legislation and independent research.

Authors:  Mark Greener
Journal:  EMBO Rep       Date:  2008-03       Impact factor: 8.807

7.  Perceptions of adolescents students on the consumption of drugs: a case study in Lima, Peru.

Authors:  Hilda Luz Bolaños Gil; Débora Falleiros de Mello; Maria das Graças Carvalho Ferriani; Marta Angélica Iossi Silva
Journal:  Rev Lat Am Enfermagem       Date:  2008 Jul-Aug

Review 8.  Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.

Authors:  Amalia M Issa; Kathryn A Phillips; Stephanie Van Bebber; Hima G Nidamarthy; Karen E Lasser; Jennifer S Haas; Brian K Alldredge; Robert M Wachter; David W Bates
Journal:  Curr Drug Saf       Date:  2007-09

9.  The challenge of effectively communicating patient safety information.

Authors:  Bruce Hugman; I Ralph Edwards
Journal:  Expert Opin Drug Saf       Date:  2006-07       Impact factor: 4.250

10.  Communicating with patients about harms and risks.

Authors:  Andrew Herxheimer
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069
View more
  1 in total

1.  A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries.

Authors:  Joseph B Babigumira; Andy Stergachis; Hye Lyn Choi; Alexander Dodoo; Jude Nwokike; Louis P Garrison
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.